These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31416579)

  • 1. Impact of single nucleotide polymorphisms on the efficacy and toxicity of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients.
    Pérez-Ramírez C; Cañadas-Garre M; Molina MÁ; Cabeza Barrera J; Faus-Dáder MJ
    Mutat Res Rev Mutat Res; 2019; 781():63-70. PubMed ID: 31416579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
    Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
    Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of EGFR gene polymorphisms on efficacy and prognosis in advanced non-small cell lung cancer treated with EGFR-TKIs].
    Da L; Xu L
    Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):162-5. PubMed ID: 23514947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
    Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of patients with advanced non-small cell lung cancer.
    Zhang JW; Zhao YY; Guo Y; Xue C; Hu ZH; Huang Y; Zhao HY; Zhang J; Wu X; Fang WF; Ma YX; Zhang L
    Chin J Cancer; 2014 Feb; 33(2):105-14. PubMed ID: 23816558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation.
    Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciadiello F; Gridelli C
    Curr Med Chem; 2012; 19(20):3337-52. PubMed ID: 22664249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer
with Uncommon EGFR Mutations].
    Du W; Wo Y; Lu T; Wang Y; Jiao W
    Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):590-599. PubMed ID: 31526464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors.
    Chang IS; Jiang SS; Yang JC; Su WC; Chien LH; Hsiao CF; Lee JH; Chen CY; Chen CH; Chang GC; Wang Z; Lo FY; Chen KY; Wang WC; Chen YM; Huang MS; Tsai YH; Su YC; Hsieh WS; Shih WC; Shieh SH; Yang TY; Lan Q; Rothman N; Chen CJ; Chanock SJ; Yang PC; Hsiung CA
    Am J Respir Crit Care Med; 2017 Mar; 195(5):663-673. PubMed ID: 27669169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
    Linardou H; Dahabreh IJ; Bafaloukos D; Kosmidis P; Murray S
    Nat Rev Clin Oncol; 2009 Jun; 6(6):352-66. PubMed ID: 19483740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
    Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
    Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
    Ariyasu R; Yanagitani N; Tadokoro K; Yamaguchi T; Uchibori K; Kitazono S; Fujita N; Katayama R; Nishio M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):517-525. PubMed ID: 32948919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
    Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
    Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogene HSPH1 modulated by the rs2280059 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Li Y; Zhang N; Zhang L; Song Y; Liu J; Yu J; Yang M
    Carcinogenesis; 2020 Sep; 41(9):1195-1202. PubMed ID: 32815538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
    Yang L; Yang S; Liu Y; Li J; Hu X; Wang Y; Zhang Y; Wang Y
    Thorac Cancer; 2018 Jun; 9(6):693-698. PubMed ID: 29655198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.